|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | New challenges in perioperative management of pancreatic cancer显示文摘Pancreatic ductal adenocarcinoma(PDAC)is the fourth leading cause of cancer-related death in the industrialized world.Despite progress in the understanding of the molecular and genetic basis of this disease,the5-year survival rate has remained low and usually does not exceed 5%.Only 20%-25%of patients present with potentially resectable disease and surgery represents the only chance for a cure.After decades of gemcitabine hegemony and limited therapeutic options,more active chemotherapies are emerging in advanced PDAC,like 5-Fluorouracil,folinic acid,irinotecan and oxaliplatin and nab-paclitaxel plus gemcitabine,that have profoundly impacted therapeutic possibilities.PDAC is considered a systemic disease because of the high rate of relapse after curative surgery in patients with resectable disease at diagnosis.Neoadjuvant strategies in resectable,borderline resectable,or locally advanced pancreatic cancer may improve outcomes.Incorporation of tissue biomarker testing and imaging techniques into preoperative strategies should allow clinicians to identify patients who may ultimately achieve curative benefit from surgery.This review summarizes current knowledge of adjuvant and neoadjuvant treatment for PDAC and discusses the rationale for moving from adjuvant to preoperative and perioperative therapeutic strategies in the current era of more active chemotherapies and personalized medicine.We also discuss the integration of good specimen collection,tissue biomarkers,and imaging tools into newly designed preoperative and perioperative strategies. | Francesco Puleo Raphaёl Maréchal Pieter Demetter Maria-Antonietta Bali Annabelle Calomme Jean Closset Jean-Baptiste Bachet Jacques Deviere Jean-Luc Van Laethem | 2015 | World Journal of Gastroenterology2015，21，8： | 4 |
| 2 | Would healing of the nasal and paranasal mucosa: a review 显示文摘 | Watelet JB Bachet C Gevaert P | 2002 | Am J Rhi- hal2002，16，2： | 1 |
| 3 | Thoracic en- dovascular aortic repair (TEVAR) for the treatment of aortic diseases显示文摘 | Grabenwoger M Alfonso F Bachet J | 2012 | Eur Heart J2012，33，13： | 1 |
| 4 | Sonic hedgehog and Glil expression predict outcome in resected pancreatic adenocarcinoma 显示文摘 | Mar6chal R Bachet JB Calomme A | 2015 | Clin Cancer Res2015，21，5： | 1 |
| 5 | KRAS mutations as an in- dependent prognostic factor in patients with advanced colorectal cancer treated with eetuximab 显示文摘 | Lievre A Bachet JB Boige V | 2008 | J Clin Oncol2008，26，： | 1 |
| 6 | KRAS mutations as an independent prognostic factor in pa- tients with advanced colorectal cancer treated with cetuximab 显示文摘 | Lievre A Bachet J B Boige V Cayre A Le Corre D Buc E | 2008 | J Clin Oncol2008，26，： | 1 |
| 7 | Cerebral protection during aortic arch surgery显示文摘 | Bachet J | | 0，，： | 1 |
| 8 | KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab 显示文摘 | Lievre A Bachet JB Boige V | 2008 | J Clin Oncol2008，26，： | 1 |
| 9 | K-RAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab显示文摘 | LIEVRE A BACHET J B BOIGE V | 2008 | J Clin 379 Oncol2008，26，3： | 1 |
| 10 | KRAS mutationstatus is predictive of response to cetuximab therapy in colorectalcancer 显示文摘 | LlfcVRE A BACHET JB LE CORRE D | 2006 | Cancer Res2006，66，8： | 1 |
| 11 | KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with eetuximab显示文摘 | Lievre A Bachet J B Boige V | 2008 | J Clin Onco12008，26，3： | 1 |
| 12 | KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab 显示文摘 | Lievre A Bachet JB Boige V | 2008 | J Clin Oncol2008，26，3： | 1 |
| 13 | KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer 显示文摘 | Lievre A Bachet JB Le Corre D | 2006 | Cancer Res2006，66，8： | 1 |
| 14 | Antegrade Cerebral perfusi0n with cold blod:a 13 year experience显示文摘 | Bachet J Guilmet D Goudot B | | 0，，： | 1 |
| 15 | gastrointestinal stromal tumour(GIST) and germline mutation of KIT exon 133 显示文摘 | Bachet JB Landi B Laurent-Puig P et aL Diagnosis prognosis and treatment of patients with | 2013 | Eur J Cancer2013，132，16： | 1 |
| 16 | KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab显示文摘 | Lievre A Bachet JB Boige V | 2008 | J Clin Oncol2008，26，3： | 1 |
| 17 | Modern temperature management in aortic arch surgery: the dilemma of moderate hypothermia显示文摘 | Luehr M Bachet J Mohr FW | 2014 | Eur J Cardiothorac Surg2014，45，1： | 1 |
| 18 | K-ras mutation status is predictive of response to Cctuximab therapy in colorectal cancer 显示文摘 | LIEVRE A BACHET J B Le CORRE D | 2006 | Cancer Res2006，66，8： | 1 |
| 19 | KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer 显示文摘 | Lievre A bachet JB Le Corre D | 2006 | Cancer Res2006，66，： | 1 |
| 20 | Brain protection during surgery of the aortic arch显示文摘 | Bachet J Guilmet D | 2002 | J Card Surg2002，17，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员